Skip to main content
OpenTrials
Completed

NCT Number: NCT05916066

Nicotinamide and Glaucoma

The investigators will include different subgroups of open-angle glaucoma and healthy controls. The participants will attend two visits with two weeks apart. At each visit the participants will have blood drawn and will undergo OCT examination. In between the two visits, participants will receive a treatment of Nicotinamide 1,5g/day for one week and 3.0g/day for the second week.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Clinical Science, Ophthalmology, Umeå University

Umeå, Västerbotten County, 90187, Sweden

About this study

The investigators plan to recruit four groups, each containing 30 subjects: 1) pseudoexfoliative glaucoma, 2) High tension open-angle glaucoma, 3) Normal tension glaucoma 4) Age-matched controls. Those enrolled will undergo two visits including an ophthalmic exam, blood sampling, and at the first visit, distribution of nicotinamide tablets. We plan to recruit participants amongst glaucoma patients already followed at the Eye Clinic at Umeå University Hospital. Furthermore, age-matched controls will be recruited through lists from the population register at Statistics Sweden. Before enrolling any subject, they will receive both oral and written information as well as sign a consent form. Furthermore, they will be evaluated to make sure that they fulfill the inclusion- and exclusion criteria prior to inclusion.

The ophthalmic exam includes measurement of IOP, perimetry, and OCT/A. Between visits, the participants will receive 1,5 grams of NAM per day the first week and 3 grams per day the second week. The blood drawn will initially be sent to Biobanken Norr for storage. Samples will then be sent to the Swedish Metabolomics Centre, Umeå University and Department of Medical Biochemistry and Biophysics, Karolinska University for analysis using high-resolution mass spectrometry.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for glaucoma patients:

  • Manifest glaucoma (PEXG, HTG, NTG) in one or two eyes,
  • age > 18 years,
  • replicable visual field defects that cannot be explained by any other disease or insult,
  • suspect/anomalous optic nerve head or abnormalities in the retinal nerve fiber layer.

Inclusion criteria

for age-matched controls:

-A normal visual field and optic nerve, age > 18 years.

Exclusion criteria

for all:

  • Any disease affecting retinal function (such as more than mild macular degeneration or diabetic retinopathy), neurological or other non-glaucomatous conditions that may affect the visual field,
  • inability to perform a perimetric exam,
  • resistance in quitting intake of multivitamins or B-vitamins,
  • allergy to NAM or niacin, previous eye surgery involving the central retina,
  • pregnant or breast-feeding women,
  • fertile women not using reliable contraception,
  • diagnosis of cancer in the last five years (not including treated squamous cell carcinoma), anamnesis of liver-disease or peptic ulcer,
  • not able to speak and understand either Swedish or English.

Treatment and study plan

Nicotinamide

Dietary Supplement

Tabletts of 500mg Nicotinamide (B3-vitamin)

Primary outcomes

  1. Plasma level of NAM before and after NAM treatment in all groups

    Time frame: Two weeks

    Are NAM levels in plasma lower in patients with glaucoma compared to healthy controls and will a short-term treatment with NAM raise the plasma concentration of NAM?

Secondary outcomes

  1. Perfusion density and flow index in macula and optic nerve head before and after NAM treatment in all gropus

    Time frame: Two weeks

    Will a short-term treatment with NAM influence the retinal vasculature measured with OCTA?

Sponsors and collaborators

Lead sponsor

Umeå University

Other

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jun 23, 2023
Registry last updated
Jun 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.